Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genoveffa Franchini

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Clinical Immunology (Orlando, Fla.)|September 18, 2014
Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesAntonio Valentin, Katherine McKinnon, Jinyao Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaquesAnna Hryniewicz, David A Price, Marcin Moniuszko, et al.
Nature Communications|September 29, 2025
HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaquesMassimiliano Bissa, Mohammad Arif Rahman, Luca Schifanella, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 4, 2016
Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 AcquisitionShari N Gordon, Namal P M Liyanage, Melvin N Doster, et al.
Clinical Immunology (Orlando, Fla.)|June 8, 2014
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responsesDiego A Vargas-Inchaustegui, Iskra Tuero, Venkatramanan Mohanram, et al.
Nature Communications|October 22, 2024
Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific responseMohammad Arif Rahman, Massimiliano Bissa, Hanna Scinto, et al.
Plos Pathogens|August 29, 2018
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7Sakaorat Lertjuthaporn, Claudia Cicala, Donald Van Ryk, et al.
Plos Pathogens|March 13, 2020
Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisitionGiacomo Gorini, Slim Fourati, Monica Vaccari, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Clinical Immunology (Orlando, Fla.)|September 18, 2014
Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesAntonio Valentin, Katherine McKinnon, Jinyao Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaquesAnna Hryniewicz, David A Price, Marcin Moniuszko, et al.
Nature Communications|September 29, 2025
HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaquesMassimiliano Bissa, Mohammad Arif Rahman, Luca Schifanella, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 4, 2016
Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 AcquisitionShari N Gordon, Namal P M Liyanage, Melvin N Doster, et al.
Clinical Immunology (Orlando, Fla.)|June 8, 2014
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responsesDiego A Vargas-Inchaustegui, Iskra Tuero, Venkatramanan Mohanram, et al.
Nature Communications|October 22, 2024
Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific responseMohammad Arif Rahman, Massimiliano Bissa, Hanna Scinto, et al.
Plos Pathogens|August 29, 2018
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7Sakaorat Lertjuthaporn, Claudia Cicala, Donald Van Ryk, et al.
Plos Pathogens|March 13, 2020
Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisitionGiacomo Gorini, Slim Fourati, Monica Vaccari, et al.
Pageof 17